Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 12:23pm CEST

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
12:55p ASTRAZENECA : lobbies for personalized asthma care with new visual snapshot tool
10:16a ASTRAZENECA : US FDA accepts regulatory submission for Lynparza in metastatic br..
10/19 ASTRAZENECA : Researchers from AstraZeneca Report on Findings in Disease Progres..
10/19 ASTRAZENECA : TAGRISSO® osimertinib Granted Breakthrough Therapy Designation by ..
10/19 ASTRAZENECA : Findings on Antibiotics Reported by Investigators at AstraZeneca (..
10/19 ASTRAZENECA : Reports Outline Obesity, Fitness and Wellness Study Results from A..
10/19 ASTRAZENECA : US FDA accepts supplemental Biologics License Application for IMFI..
10/18 ASTRAZENECA : Announces New Data Showing US Preterm Infants at Significantly Gre..
10/18 ASTRAZENECA : US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
10/18 FDA ACCEPTS ASTRAZENECA PLC (ADR)(NY : AZN) Imfinzi’s Supplemental Biologi..
More news
News from SeekingAlpha
04:16a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 19, 2017
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/18 FDA accepts Myriad Genetics' application for companion diagnostic test for As..
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
Financials ($)
Sales 2017 21 558 M
EBIT 2017 5 959 M
Net income 2017 2 524 M
Debt 2017 12 193 M
Yield 2017 4,00%
P/E ratio 2017 30,76
P/E ratio 2018 25,99
EV / Sales 2017 4,58x
EV / Sales 2018 4,52x
Capitalization 86 495 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 66,4 $
Spread / Average Target -2,5%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA16.62%86 419
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372